Is AbbVie a Buy After Its Purchase of Apogee?

Published June 25, 2026 · Category: Finance

Overview

Pharmaceutical giant AbbVie (NYSE: ABBV) made a bold move this past Monday when it announced its planned $10.9 billion acquisition of Apogee Therapeutics (NASDAQ: APGE).

The deal would bring a promising immunology drug, zumilokibart, into AbbVie's pipeline. This is a drug that many see as competing with Dupixent from Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) as a treatment for moderate to severe atopic dermatitis, the most common form of eczema.

Details

AbbVie said it would pay $135.11 a share in cash, a 49% premium to Apogee's closing price last week of $90.38. Here are two reasons to buy AbbVie stock if the deal goes through, and one reason to stand on the sidelines.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• Inside Wealth: Luxury spending now driven by experiences and 'inheritourism'
• Apple’s MacBooks and iPads are getting more expensive as the memory crunch deepens
• Micron is soaring after blowout earnings report. That's good news for this other memory chipmaker, Citigroup says